ASLAN Pharmaceuticals

You are now leaving our web site.

The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.

ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.

I understand

News & Publications

Read about our latest product developments and partnerships, industry advances and events.

News

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on its clinical development activities.

For more information, please refer to the English press release.